March 9, 2018—Diaceutics, based in Dundalk, Ireland, will collaborate with tech companies Lenovo and Intel to leverage their vast proprietary database of patient testing data.
Diaceutics will use artificial intelligence to see whether patients can be grouped according to diagnostic test information in hopes the data can help identify ways to improve diagnosis, treatment, and outcomes for patients with similar characteristics. The company will use Lenovo’s ThinkStation P920, powered by Intel Xeon scalable processors, and testing data from hundreds of clinical laboratories; the machine learning system will identify similarities and patterns within the data.
“We can now look at data in a novel way. No longer will we only be making decisions based on diagnostic data. Artificial intelligence allows us to look at the complete patient journey from initial testing and diagnosis, and on to the ultimate treatment. The result will be significantly better patient testing and likely improved patient outcomes, such as longer cancer survivorship rates,” Peter Keeling, CEO of Diaceutics, said in a statement. “This collaboration is a major step in our mission to help patients, by helping them find the right precision medicine at the right time. We are using artificial intelligence to enable the world to unlock the true life-changing promise of precision medicine.”